Company intelligence
HepQuant, LLC
Transforming Liver Health
About HepQuant, LLC
HepQuant develops non-invasive, quantitative tests that measure liver health. The HepQuant DuO Test enables healthcare providers to manage patients with liver diseases more effectively. The HepQuant DuO Test delivers information about liver cell function and portal-systemic shunting, attributes of liver disease that are associated with clinical outcomes. Results may be used by a physician in conjunction with clinical evaluation and other tests to aid in the decision to proceed with or defer invasive procedures, to monitor treatment response, or to predict disease progression and adverse outcomes, such as ascites, encephalopathy and variceal bleeding.
Verified activity
Signals from HepQuant, LLC
4 published signals
Research & Knowledge
HepQuant, LLC published a study exploring the use of genetically engineered pig livers to temporarily support liver function of human decedents using extracorporeal liver cross-circulation (ELC).
Reported by HepQuant, LLC
Research & Knowledge
HepQuant, LLC incorporated HepQuant testing to measure liver function simultaneously from the pig liver and the native liver of the human decedent throughout ELC support.
Reported by HepQuant, LLC
Research & Knowledge
HepQuant, LLC findings suggest that HepQuant testing could inform decisions in patients on ELC for acute or acute-on-chronic liver failure regarding maintenance of ELC or proceeding to transplantation.
Reported by HepQuant, LLC
Legal & Regulatory
HepQuant, LLC notes that the FDA cleared a clinical trial of up to 20 subjects with liver failure for treatment with eGenesis's pig liver (EGEN-5784) with OrganOx's ELC.
Reported by HepQuant, LLC